A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.
Stanford researchers developed a first-in-class small-molecule inhibitor of the CLC-2 ion channel for research and drug development. CLC-2 is part of the CLC family of chloride ion channels, which regulate the flux of chloride ions across cell membranes.
Stanford researchers have designed a non-invasive, low power ultrasonic neuromodulation device which can target tissue deep in the brain with high spatial-temporal resolution.
Engineers at the Khuri-Yakub Group have designed a non-surgical alternative for treating epilepsy using ultrasonic technology which can detect, localize, and suppress epileptic seizures in epileptic patients.